The availability of new drugs offers the opportunity to improve the outcome of locally advanced rectal cancer. Raltitrexed and oxaliplatin are effective in advanced colorectal cancer with acceptable toxicity and can act as radiation enhancers as shown in phase 1-11 studies. The aim of the study was thus to determine the recommended dose of oxaliplatin concomitantly administered with raltitrexed and concurrent preoperative radiotherapy in patients with stage 11-111 extraperitoneal rectal cancer.
Methods
From September 2001 to September 2002, 18 consecutive patients with T3/T4 rectal cancer were treated at our Institution with preoperative chemoradiation followed by surgery after 6-8 weeks. Pelvic radiotherapy was delivered at a dose of 45 Gy in 25 fractions in 5 weeks followed by a 5.4 Gy boost at 1.8 Gy daily. Concomitant chemotherapy consisted of 3 mg/m2/iv of raltitrexed on days 1, 19, 38 of radiotherapy treatment with incremental doses of oxaliplatin according to dose finding rules (4 dose levels: 65, 85, 110, 130 mg/m2). Dose-limiting toxicity for oxaliplatin was defined as either grade 3-4 hematological or grade 3-4 gastrointestinal or neurological toxicity. We studied a minimum of 3 patients at each dose level.
Results
Three patients were treated at 65, 85, and 110 mg/m2/iv, respectively, while 9 patients were recruited at the last dose level. Neither grade 3-4 gastrointestinal nor neurological toxicity were documented. Dose-limiting toxicity was documented in 2/9 subjects at the 130 mg/m2 level consisting of grade 3 transient asymptomatic leukopenia. Thirteen patients developed transient increase of one or more liver enzymes (grade 3-4) and 2 patients developed grade 3 perineal dermatitis. All patients received the programmed dose of radiotherapy. The chemotherapy regimen was not completed in 4 cases due to grade 2 protracted leukopenia.
Conclusions
The maximum tolerated dose of oxaliplatin was not reached at the maximum dose level (IV); 130 mg/m2 can therefore be defined as the recommended dose. The combination of oxaliplatin with raltitrexed and radiotherapy can be considered feasible and well tolerated.
HealdR.J., KaranjiaN.D.: Results of radical surgery for rectal cancer.World J Surg, 16: 848–857, 1992.
2.
EnkerW.E.: Designing the optimal surgery for rectal carcinoma.Cancer, 78: 1847–1850, 1996.
3.
Gastrointestinal Tumor Study Group:Prolongation of the disease-free interval in surgically treated rectal carcinoma.N Engl J Med,312: 1465–1472, 1985.
4.
Gastrointestinal Tumor Study Group:Radiation therapy and fluorouracil with or without semustine for the treatment of patients with surgical adjuvant adenocarcinoma of the rectum.J Clin Oncol, 10: 549–557, 1992.
National Institutes of Health Consensus Conference: Adjuvant therapy for patients with colon and rectal cancer.JAMA, 264: 1444–1450, 1990.
8.
FreedmanG.M., CoiaL.R.: Adjuvant and neoadjuvant treatment of rectal cancer.Semin Oncol, 22: 611–624, 1995.
9.
CapirciC., PolicoC., MandolitiG.: Dislocation of small bowel volume within box pelvic treatment fields, using new “up down table” device.Int J Radiat Oncol Biol Phys, 51: 465–473, 2001.
10.
MinskyB.D., ContiJ.A., HuangY., KnopfK.: Relationship of acute gastrointestinal toxicity and the volume of irradiated small bowel in patients receiving combined modality therapy for rectal cancer.J Clin Oncol, 13: 1409–1416, 1995.
11.
MarijnenC.A., GlimeliusB.: The role of radiotherapy in rectal cancer.Eur J Cancer, 38: 943–952, 2002.
O'ConnellM.J., MartensonJ.A., WieandH.S., KrookJ.E., Mac-DonaldJ.S., HallerD.J., MayerR.J., GundersonL.L., RichT.A.: Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery.N Engl J Med, 331: 502–507, 1994.
14.
SmalleyS.R., BenedettiJ., WilliamsonS., RobertsonJ., FisherB., MartensonJ., BensonA.B., RobertM., CrippsC., MacDon-aldJ.: Intergroup 0144 – phase III trial of 5-FU-based chemotherapy regimens plus radiotherapy (XRT) in postoperative adjuvant rectal cancer. Bolus 5-FU vs prolonged venous infusion (PVI) before and after XRT + PVI vs bolus 5-FU + leucovorin (LV) + levamisole (LEV) before and after XRT + bolus 5-FU + LV.Proc ASCO, 22: abst.1006, 2003.
15.
RichT.A., ShepardR.C., MosleyS.T.: Four decades of continuing innovation with fluorouracil: current and future approaches to fluorouracil chemoradiation therapy.J Clin Oncol, 22: 2214–2232, 2004.
16.
LupattelliM., MaranzanoE., BellavitaR., TarducciR., LatiniR., CastagnoliP., BufalariA., CorgnaE., PinagliaD., RossettiR., RibacchiR., LatiniP.: Adjuvant radiochemotherapy in high-risk rectal cancer. Results of a prospective non-randomized study.Tumori, 87: 240–248, 2001.
17.
ValentiniV., CocoC., CelliniN., PicciocchiA., FaresC., Roset-toM.E., MantiniG., MorgantiA.G., BarbaroB., CogliandoloS., NuzzoG., TedescoM., Ambesi-ImpiombatoF., CosimelliM., RotmanM.: Ten years of preoperative chemoradiation for extraperitoneal T3 rectal cancer: acute toxicity, tumor response and sphincter preservation in three-year consecutive studies.Int J Radiat Oncol Biol Phys, 51: 371–383, 2001.
18.
TouroutoglouN., PazdurR.: Thymidylate synthase inhibitors.Clin Cancer Res, 2: 227–243, 1996.
19.
ClarkeS.J., HanwellJ., De BoerM., PlantingA., VerweijJ., WalkerM., SmithR., JackmanA.L., HughesL.R., HarrapK.R., KennealeyG.T., JudsonI.R.: Phase I trial of ZD 1694, a new folate-based thymidylate synthase inhibitor, in patients with solid tumours.J Clin Oncol, 14: 1495–1503, 1996.
20.
CunninghamD., ZalcbergJ.R., RathU., OliverI., van CutsemE., SvenssonC., SeitzJ.F., HarperP., KerrD., Perez-MangaG; the Tomudex Colorectal Cancer Study Group: Final results of a randomized trial comparing “Tomudex” (raltitrexed) with 5-fluorouracil plus leucovorin in advanced colorectal cancer.Ann Oncol, 7: 961–965, 1996.
21.
CocconiG., CunninghamD., van CutsemE., FrancoisE., Gus-tavssonB., van HazelG., KerrD., PossingerK., HietscholdS.M.: Open, randomized, multicenter trial of raltitrexed versus fluorouracil plus high-dose leucovorin in patients with advanced colorectal cancer. Tomudex Colorectal Cancer Study Group.J Clin Oncol, 16: 2943–2952, 1998.
22.
HarperP.: Advanced colorectal cancer (ACC): results from the latest “Tomudex” (raltitrexed) comparative study (abstr).Proc ASCO, 16: 802, 1997.
23.
CunninghamD.: Mature results from three large controlled studies with raltitrexed (“Tomudex”).Br J Cancer, 77: 15–21, 1998.
24.
TeicherB.A., AraG., ChenY.N., RechtA., ColemanC.N.: Interaction of tomudex with radiation in vitro and in vivo.Int J Oncol, 13: 437–442, 1998.
25.
JamesR., PriceP., ValentiniV.: Raltitrexed (Tomudex) concomitant with radiotherapy as adjuvant treatment for patients with rectal cancer: preliminary results of phase I studies.Eur J Cancer, 35: S19–22, 1999.
26.
GambacortaM.A., ValentiniV., MorgantiA.G., MantiniG., MiccicheF., RattoC., Di MiceliD., BarbaroB., RotondiF., AlfieriS., DogliettoG.B., Garcia-VargasJ., De PaoliA., RossiC., CelliniN.: Chemoradiation with raltitrexed (tomudex) in preoperative treatment of stage II-III resectable rectal cancer: a phase II study.Int J Radiat Oncol Biol Phys, 60: 130–138, 2004.
27.
LupattelliM., MaranzanoE., BellavitaR., NataliniG., CorgnaE., RossettiR., TrippaF., MascioniF., SidoniA., AnselmoP., BuzziF., BrugiaM., LatiniP.: Raltitrexed and radiotherapy as adjuvant treatment for stage II-III rectal cancer: a feasibility study.Tumori, 91: 498–504, 2005.
28.
MamentaE.L., PomaE.E., KaufmannW.K., DelmastroD.A., GradyH.L., ChaneyS.G.: Enhanced replicative bypass of plat-inum-DNA adducts in cisplatin-resistant human ovarian carcinoma cell lines.Cancer Res, 54: 3500–3505, 1994.
29.
PendylaL., CreavenP.J., ShahG.: In vitro cytotoxicity studies of oxaliplatin in human tumor cell lines.Proc Am Cancer Res, 32: 410, 1991.
30.
SeitzJ.F., BennounaJ., PaillotB., GamelinE., FrancoisE., ConroyT., RaoulJ.L., BecouarnY., Bertheault-CvitkovicF., YchouM., NascaS., FandiA., BarthelemyP., DouillardJ.Y.: Multicenter non-randomized phase II study of raltitrexed (tomudex) and oxaliplatin in non-pretreated metastatic colorectal cancer patients.Ann Oncol, 13: 1072–1079, 2002.
31.
CascinuS., GrazianoF., FerrauF., CatalanoV., MassacesiC., SantiniD., SilvaR.R., BarniS., ZaniboniA., BattelliN., SienaS., GiordaniP., MariD., BaldelliA.M., AntognoliS., MaisanoR., PrioloD., PessiM.A., ToniniG., RotaS., LabiancaR.: Raltitrexed plus oxaliplatin (TOMOX) as first-line chemotherapy for metastatic colorectal cancer: a phase II study of the Italian Group for the Study of Gastrointestinal Tract Carcinomas (GISCAD).Ann Oncol, 13: 716–720, 2002.
32.
ScheithauerW., KornekG.V., SchuellB., Ulrich-PurH., PenzM., RadererM., LangF., SchneeweissB., LenauerA., DepischD.: Second-line treatment with oxaliplatin + raltitrexed in patients with advanced colorectal cancer failing fluoropyrimi-dine/leucovorin-based chemotherapy.Ann Oncol, 12: 709–714, 2001.
33.
ICRU report 50:Prescribing, recording and reporting photon beam therapy.International Commission on Radiation Units and Measurements, Bethesda, Maryland, 1993.
34.
MillerA.B., HoogstratenB., StaquetM., WinklerA.: Reporting results of cancer treatment.Cancer, 47: 207–214, 1981.
35.
PerezC.A., BradyL.W.: Overview. In: Principles and practice of radiation oncology,PerezC.A., BradyL.W. (Eds), 2nd ed, pp 1–62, Lippincott, Philadelphia, 1992.
36.
MandardA.M., DalibardF., MandardJ.C., MarnayJ., Henry-AmarM., PetiotJ.F., RousselA., JacobJ.H., SegolP., SamamaG., OllivierJ.M., BonvalotS., GignouxM.: Pathologic assessment of tumor regression grade after preoperative chemoradiotherapy of esophageal carcinoma: clinicopathologic correlations.Cancer, 73: 2680–2686, 1994.
37.
BossetJ.F., CalaisG., DabanA., BergerC., Radosevic-JelicL., MaingonP., BardetE., PierartM., BriffauxA.: EORTC Radiotherapy Group: Preoperative chemoradiotherapy versus preoperative radiotherapy in rectal cancer patients: assessment of acute toxicity and treatment compliance. Report of the 22921 randomised trial conducted by the EORTC Radiotherapy Group.Eur J Cancer, 40: 219–224, 2004.
38.
ShumateC.R., RichT.A., SkibberJ.M., AjaniJ.A., OtaD.M.: Preoperative chemotherapy and radiation therapy for locally advanced primary and recurrent rectal carcinoma: a report of surgical morbidity.Cancer, 7: 3690–3696, 1993.
39.
GrannA., MinskyB.D., CohenA.M., SaltzL., GuillemJ.G., PatyP.B., KelsenD.P., KemenyN., IlsonD., Bass-LoebJ.: Preliminary results of preoperative 5-fluorouracil, low-dose leucovorin, and concurrent radiation therapy for clinically resectable T3 rectal cancer.Dis Colon Rectum, 40: 515–522, 1997.
40.
GambacortaM.A., ValentiniV., CocoC., MorgantiA.G., Sman-iottoG., MiccicheF., MantiniG., BarbaroB., Garcia-VargasJ.E., MagistrelliP., PicciocchiA., CelliniN.: Chemoradiation with raltitrexed and oxaliplatin in preoperative treatment of stage II-III resectable rectal cancer: phase I and II studies.Int J Radiat Oncol Biol Phys, 60: 139–148, 2004.
41.
FreyerG., BossardN., RomestaingP., MornexF., ChapetO., Trillet-LenoirV., GerardJ.P.: Addition of oxaliplatin to continuous fluorouracil, 1-folinic acid, and concomitant radiotherapy in rectal cancer: the Lyon R 97-03 phase I trial.J Clin Oncol,19: 2433–2438, 2001.
42.
RodelC., GrabenbauerG.G., PapadopoulosT., HohenbergerW., SchmollH.J., SauerR.: Phase I/II trial of capecitabine, oxaliplatin, and radiation for rectal cancer.J Clin Oncol, 21: 3098–3104, 2003.
43.
LoiS., NganS.Y., HicksR.J., MukeshB., MitchellP., MichaelM., ZalcbergJ., LeongT., Lim-JoonD., MackayJ., RischinD.: Oxaliplatin combined with infusional 5-fluorouracil and concomitant radiotherapy in inoperable and metastatic rectal cancer: a phase I trial.Br J Cancer, 92: 655–661, 2005.
44.
AscheleC., FrisoM.L., PucciarelliS., LonardiS., SartorL., Fab-risG., UrsoE.D.L., Del BiancoP., SottiG., LiseM., MonfardiniS.: A phase I-II study of weekly oxaliplatin, 5-fluorouracil continuous infusion and preoperative radiotherapy in locally advanced rectal cancer.Ann Oncol, 16: 1140–1146, 2005.
45.
VecchioF.M., ValentiniV., MinskyB.D., PadulaG.D., Venkatra-manE.S., BalducciM., MiccicheF., RicciR., MorgantiA.G., GambacortaM.A., MauriziF., CocoC.: The relationship of pathologic tumor regression grade (TRG) and outcomes after preoperative therapy in rectal cancer.Int J Radiat Oncol Biol Phys, 62: 752–760, 2005.
